Verrica Pharmaceuticals Inc.
VRCA
NASDAQ·Healthcare·Biotechnology·Mkt cap $91.0M
$5.30
▼ -1.12%
P/E
-4.95
Mkt Cap
$91.0M
52-Wk Range
$3.28–$9.82
52-Week Range
$3.28 - $9.82
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 4.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Average volatility.
Growth
Strong growth ahead
Value
Deep value opportunity - significant discount to sector peers
Momentum
Weak
-11.5% over 3m
Quality
Excellent
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying VRCA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 13, 2026
AUG 6, 2026
Reported EPS of -$0.62 vs -$0.39 consensus (-60.0% surprise). Revenue of $5.9M vs $5.7M expected (+2.2%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-60.0%
Revenue trend · last 2Q
—
-54%
Q1 26
Q2 26
$5.0M
$5.9M
Margins · last 2Q
Gross
92.6%
Profit
-224.4%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How VRCA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.